Merck shakes up execs
Merck has made appointments to three top leadership positions including CEO, president and president of global human health positions.
According to the Whitehouse Station, N.J.-based company, Richard T. Clark, its current chairman, CEO and president, will continue to lead as chairman and CEO.
Kenneth C. Frazier has been appointed by the company’s board to serve as president and will report to Clark. Frazier is the current president of the Global Human Health sales and marketing division at the company.
Under the appointment Frazier will lead three of the company’s largest divisions including pharmaceutical and vaccine marketing and sales, research and development and manufacturing and supply. According to Merck, Frazier joined the company in 1992 and has since held various leadership positions including general council, senior vice president and executive vice president. The company said that Frazier was a key player in the merger with Schering-Plough.
Lastly, the company has elected Adam H. Schechter to succeed Frazier as president of the Global Human Health sales and marketing sector. According to the company, Schechter is currently in charge of the company's U.S. pharmaceutical division.
Previously, Schechter was general manager of the Merck/Schering-Plough cholesterol joint project and was first hired at the company in 1988.
According to the Whitehouse Station, N.J.-based company, Richard T. Clark, its current chairman, CEO and president, will continue to lead as chairman and CEO.
Kenneth C. Frazier has been appointed by the company’s board to serve as president and will report to Clark. Frazier is the current president of the Global Human Health sales and marketing division at the company.
Under the appointment Frazier will lead three of the company’s largest divisions including pharmaceutical and vaccine marketing and sales, research and development and manufacturing and supply. According to Merck, Frazier joined the company in 1992 and has since held various leadership positions including general council, senior vice president and executive vice president. The company said that Frazier was a key player in the merger with Schering-Plough.
Lastly, the company has elected Adam H. Schechter to succeed Frazier as president of the Global Human Health sales and marketing sector. According to the company, Schechter is currently in charge of the company's U.S. pharmaceutical division.
Previously, Schechter was general manager of the Merck/Schering-Plough cholesterol joint project and was first hired at the company in 1988.